Videos

Jennifer A. Woyach, MD, Discusses Exciting Abstracts at ASH 2021

Thomas G. Martin, MD, spoke about the abstracts regarding B-cell maturation antigen–targeted treatments he’s excited to see presented at ASH 2021.

Jennifer A. Woyach, MD

Metastatic Urothelial Carcinoma: Optimizing Frontline Maintenance Therapy

Jennifer A. Woyach, MD, spoke about which abstracts she’s most excited to see presented at the 2021 American Society of Hematology Annual Meeting.

Peter H. O’Donnell, MD, PhD;Matthew T. Campbell, MD, MS;Shilpa Gupta, MD;Cora N. Sternberg, MD

Selecting Frontline Therapy for Metastatic Urothelial Carcinoma

Shared insight on best practices in frontline maintenance therapy for metastatic urothelial carcinoma to improve patient outcomes.

Peter H. O’Donnell, MD, PhD;Matthew T. Campbell, MD, MS;Shilpa Gupta, MD;Cora N. Sternberg, MD

Upcoming Abstracts on Multiple Myeloma for Presentation at 2021 ASH

Reviewing a patient case of metastatic urothelial carcinoma, experts discuss the selection of frontline and maintenance therapy.

Nina Shah, MD

Thomas G. Martin, MD, Discusses Abstracts He’s Eagerly Anticipating for Presentation at 2021 ASH

Nina Shah, MD, touched on important abstracts being presented at the 2021 American Society of Hematology Annual Meeting.

Thomas G. Martin, MD

Optimization of Genetic Testing for mCRPC

Thomas G. Martin, MD, spoke about different abstracts to be presented at ASH 2021.

Raoul S. Concepcion, MD, FACS;Jason M. Hafron, MD, CMO;Daniel P. Petrylak, MD;Oliver Sartor, MD;Leonard G. Gomella, MD

Intriguing CLL Data From 2021 Conferences

Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.

Susan M. O’Brien, MD

Sequencing Therapy for mCRPC

Susan M. O’Brien, MD, discusses the important data from conferences in 2021 regarding chronic lymphocytic leukemia.

Raoul S. Concepcion, MD, FACS;Jason M. Hafron, MD, CMO;Daniel P. Petrylak, MD;Oliver Sartor, MD;Leonard G. Gomella, MD

Successes and Challenges with Maintenance Therapy

Daniel P. Petrylak, MD, leads the discussion on sequencing treatment for a patient with mCRPC, such as in case 2, who progresses on docetaxel therapy.

Shilpa Gupta, MD;Jason R. Brown, MD

Reflections on Future Treatment Strategies for HER2+ mBC

Shilpa Gupta, MD and Jason Brown, MD discuss trials with successful or negative results with maintenance therapy.

Andrew D. Seidman, MD;Aditya Bardia, MD, MPH;Mark D. Pegram, MD;Ruta Rao, MD

Patient Case #3: Sequencing Therapy and Monitoring Results

Experts close out their discussion on the management of HER2+ metastatic breast cancer by highlighting their hopes for future treatment strategies.

Andrew D. Seidman, MD;Aditya Bardia, MD, MPH;Mark D. Pegram, MD;Ruta Rao, MD

Audience Questions on Selecting Optimal Therapy for mBC

Centering their conversation on a patient case, experts discuss the sequencing and monitoring of therapy in patients with HER2+ metastatic breast cancer.

Andrew D. Seidman, MD;Aditya Bardia, MD, MPH;Mark D. Pegram, MD;Ruta Rao, MD

Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma

Panelists field questions from a live audience regarding the optimal selection of therapy for patients with metastatic breast cancer.

Nina Shah, MD

Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma

Nina Shah, MD, highlights some of the major takeaways in multiple myeloma from the 2021 European Hematology Association Congress.

Nina Shah, MD

Major Breakthroughs in Treating Chronic Lymphocytic Leukemia

Nina Shah, MD, discusses breakthroughs in the treatment of multiple myeloma throughout the preceding year.

Susan M. O’Brien, MD

Second-Line Therapy for High-Risk Primary Myelofibrosis

Susan M. O'Brien, MD, discusses breakthroughs in the treatment of chronic lymphocytic leukemia throughout the preceding year.

John O. Mascarenhas, MD;Raajit Rampal, MD, PhD;Srdan Verstovsek, MD, PhD

Second-Line Treatment Options for Myelofibrosis

Second-line treatment considerations for a 75-year-old man with high-risk primary myelofibrosis who was previously treated with ruxolitinib.

Srdan Verstovsek, MD, PhD;Raajit Rampal, MD, PhD;John O. Mascarenhas, MD

Patient Case 1: Discussion

Second-line therapies for myelofibrosis that are available or in the pipeline for use.

December 3rd 2021

The panel continues their conversation about the first patient case.

Patient Case 1: A 65-Year-Old Man With RCC

December 3rd 2021

Toni Choueiri, MD, introduces the first patient case: a 65-year-old man with advanced-stage renal cell carcinoma.

Exciting Advances in the Therapeutic Space and Clinical Pearls for Treating Metastatic Prostate Cancer

Sequencing Strategies for Metastatic Castration-Resistant Prostate Cancer Therapy

Alicia Morgans, MD, MPH, lists several advances being made while treating metastatic prostate cancer and offers advice to clinicians who don’t see patients with the disease very often.

Updated Safety Data and Treatment Selection in nmCRPC

An expert examines sequencing strategies for the treatment of metastatic prostate cancer.

Adverse Events with Next-Generation Androgen Receptor Inhibitors in nmCRPC

Dr Aaron Berger shares updated safety data on next-generation androgen receptor inhibitors and impact of safety profile on treatment selection in nmCRPC.

Unmet Needs and Future Directions

Aaron Berger, MD, discusses adverse events with enzalutamide, apalutamide and darolutamide and their management.

Cancer Network Editors

Treatment Selection for Patients With EGFR Exon 20 Insertions in NSCLC

Zofia Piotrowska, MD, discusses unmet needs, novel treatment strategies and future perspectives for patients with EGFR exon 20-positive NSCLC.

Cancer Network Editors

Mobocertinib for the Treatment of EGFR Exon 20 Insertions in NSCLC

Zofia Piotrowska, MD, shares insights on factors to consider when selecting the appropriate therapy for patients with EGFR exon 20-positive NSCLC.

Cancer Network Editors